Addendum
Atezolizumab (NSCLC, first line) – Addendum to Project A24-97
Report documents
-
Addendum
Atezolizumab (NSCLC, first line) – Addendum to Project A24-97
Dossier assessment
Indication:
First-line treatment of advanced non-small cell lung cancer in adult patients for whom platinum-based chemotherapy is not an option and whose tumours have no EGFR mutations or ALK translocations
Result of dossier assessment:
after addendum now:
- Patients with PD-L1 expression ≥ 50% on tumour cells: added benefit not proven
- Patients with PD-L1 expression < 50% on tumour cells: indication of minor added benefit
Additional information
Federal Joint Committee (G-BA)
2025-03-20 A G-BA decision was published.
Project details
- Project no.
- A25-25
- Commission
- Commission awarded on 11.02.2025 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A25-25_en
Connected Projects
-
Dossier assessment
Atezolizumab (NSCLC) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed